Presentation Will Describe the Future of Aging Research and iTRTM,
an Emerging Area of Research from BioTime
Dr. West to also Serve on Panel: “Unleashing Regenerative Medicine to
Extend the Healthy Lifespan”
ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 8, 2016--
BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company
developing and commercializing products addressing degenerative
diseases, today announced that Co-Chief Executive Officer Michael D.
West, Ph.D., is delivering a Plenary Presentation at the World
Stem Cell Summit at the Palm
Beach County Convention Center in West Palm Beach, Florida.
In Dr. West’s presentation, “The
Future of Human Aging: Implications of Induced Tissue Regeneration,”
he will put in perspective his previous work on the immortalizing enzyme
designated telomerase, pluripotent stem cell and reprogramming
technology, and the emerging field of induced tissue regeneration (iTRTM)
for future interventions in the biology of human aging. BioTime,
together with its collaborator Insilico
announced a collaboration on an artificial intelligence (AI)-driven
resource designed to facilitate the discovery of iTR-based treatments
that could enable the body to repair tissue damage, without scarring. In
his presentation, Dr. West will describe the biological basis of this
new technology, being led by BioTime.
Dr. West will deliver the presentation on Thursday, December 8, from
4:15 p.m. to 5:15 p.m. EST in the Grand Ballroom of the Palm Beach
County Convention Center. It will be live-streamed on the World
Stem Cell Summit website and posted to BioTime’s YouTube
channel in the days following the event.
Additionally, Dr. West will serve on a panel, “Unleashing
Regenerative Medicine to Extend the Healthy Lifespan: Technological
Issues and Commercial Opportunities,” on December 8 at 11:00 a.m.
BioTime, Inc. is a clinical-stage biotechnology company focused on
developing and commercializing novel therapies developed from what the
company believes to be the world’s premier collection of pluripotent
cell assets. The foundation of BioTime’s core therapeutic technology
platform is pluripotent cells that are capable of becoming any of the
cell types in the human body. Pluripotent cells have potential
application in many areas of medicine with large unmet patient needs,
including various age-related degenerative diseases and degenerative
conditions for which there presently are no cures. Unlike
pharmaceuticals that require a molecular target, therapeutic strategies
based on the use of pluripotent cells are generally aimed at
regenerating or replacing affected cells and tissues, and therefore may
have broader applicability than pharmaceutical products.
In addition to the development of therapeutics, BioTime’s research and
other activities have resulted, over time, in the creation of other
subsidiaries that address other non-therapeutic market opportunities
such as cancer diagnostics, drug development and cell research products,
and mobile health software applications.
BioTime common stock is traded on the NYSE MKT and TASE under the symbol
BTX. For more information, please visit www.biotimeinc.com
or connect with the company on Twitter,
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://news.biotimeinc.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161208005838/en/
Source: BioTime, Inc.
EVC Group, Inc.
Matt Haines, 917-733-9297
Gotham Communications, LLC
Bill Douglass, 646-504-0890